Disrupted TH17/Treg Balance in Patients with Chronic Low Back Pain by Luchting, Benjamin et al.
Disrupted TH17/Treg Balance in Patients with Chronic
Low Back Pain
Benjamin Luchting*, Banafscheh Rachinger-Adam, Julia Zeitler, Lisa Egenberger, Patrick Möhnle,
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Abstract
Chronic low back pain (CLBP) is a leading cause of disability and costs in health care systems worldwide. Despite extensive
research, the exact pathogenesis of CLBP, particularly the individual risk of chronification remains unclear. To investigate a
possible role of the adaptive immune system in the pathophysiology of CLBP, we analyzed T cell related cytokine profiles, T
cell related mRNA expression patterns and the distribution of T cell subsets in 37 patients suffering from nonspecific CLBP
before and after multimodal therapy in comparison to 25 healthy controls. Serum patterns of marker cytokines were
analyzed by Luminex technology, mRNA expression of cytokines and specific transcription factors was measured by real-
time PCR, and distribution of TH1-, TH2-, TH17- and regulatory T cell (Tregs) subsets was determined by multicolor flow
cytometry. We found that CLBP patients exhibit an increased number of anti-inflammatory Tregs, while pro-inflammatory
TH17 cells are decreased, resulting in an altered TH17/Treg ratio. Accordingly, FoxP3 and TGF-b-mRNA expression was
elevated, while expression of IL-23 was reduced. Serum cytokine analyses proved to be unsuitable to monitor the adaptive
immune response in CLBP patients. We further show that even after successful therapy with lasting reduction of pain, T cell
subset patterns remained altered after a follow-up period of 6 months. These findings suggest an involvement of TH17/Treg
cells in the pathogenesis of CLBP and emphasize the importance of these cells in the crosstalk of pain and immune
response.
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Introduction
Low back pain (LBP) is a common condition with a lifetime
prevalence of nearly 84%. Although most patients recover
completely within 4–8 weeks, a subset of patients is prone to
develop chronic low back pain (CLBP). CLBP has become a major
challenge for public health care systems worldwide [1]. The
prevalence of CLBP is about 23%; around 12% of the afflicted
patients are severely disabled [2,3]. Still, mechanisms driving the
chronification of low back pain syndromes remain largely elusive.
Pathological physical conditions such as microtraumata, incorrect
posture and degenerative processes as well as psychological factors
such as overtaxing, emotional distress and inadequate coping have
been described to contribute to the pathogenesis of CLBP [4,5].
Increasing evidence indicates a pivotal role of the immune system
in acute and chronic pain [6].
Recent studies have reported enhanced serum levels of pro-
inflammatory cytokines in various pain syndromes [7,8,9,10]. In
the pathogenesis of CLBP, a possible impact of TNF-a was
suggested [11]. Moreover, an increased expression of Il-17 in
herniated and degenerated lumbar intervertebral discs has been
reported, indicating a possible role of this cytokine in the
chronification of pain [9].
While the innate immune system has been found to play an
important role in acute pain [12], T-Lymphocytes as key players of
the adaptive immune system are supposed to be of major
importance [13,14] in the pathogenesis of chronic pain. In
patients with complex regional pain syndrome (CRPS) and in
those suffering from abacterial chronic pelvic pain [15,16], a
TH1/TH2 imbalance with increased numbers of TH1 cells has
been shown. In recent years, TH1/TH2 dichotomy has been
expanded by two further CD4+ T cell lineages, Th17 and
regulatory T cells (Tregs). These two T-cell subsets play prominent
roles in immune functions: Th17 cells exerting pro-inflammatory
effects are key players in the pathogenesis of autoimmune diseases
and protection against bacterial infections, while Tregs function to
restrain excessive effector T-cell responses. The role of both T cell
subsets has extensively been analyzed in tumor growth and in the
development of inflammatory and autoimmune diseases
[17,18,19,20,21]. Recently published data also indicate an
involvement of both T cell subsets in the development of chronic
pain [22,23,24,25]. For example, in patients with postherpetic
neuralgia (PHN), increased Treg numbers have been found [26].
In addition, there is evidence that these cells play a central role in
endogenous recovery from neuropathic pain [27]. Due to the
antagonistic functions of TH17 and Treg cells, and in analogy to
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German Clinical Trial Register: Registration Trial DRKS00005954.
the well-known TH1/TH2 paradigm, the ratio between TH17
and Tregs is increasingly used to characterize immune responses.
In CLBP, however, specific alterations in the adaptive immune
system have not conclusively been analyzed, yet.
In the current study, we investigated cytokine profiles and T
helper cell subset compositions in CLBP patients and healthy
controls. Our results indicate that CLBP is associated with
characteristic alterations of T helper cell subsets: The TH17/
Treg ratio was significantly decreased. We further provide
evidence that these alterations persist even in those patients
exhibiting significant pain reduction after participation in a
standardized multimodal therapy program.
Materials and Methods
Ethics statement
The study followed the principles of the Declaration of Helsinki
and was approved by the Ethics Committee of the LMU Munich.
Subjects
During a prospective recruitment period of two years (Septem-
ber 2011 until September 2013), all patients seeking treatment for
nonspecific CLBP at our pain clinic were assessed for study specific
inclusion and exclusion criteria. Inclusion criteria were CLBP
defined as low back pain persisting longer than two month, not
attributable to a recognized specific pathological condition (e.g.,
disc herniation, any type of radiculopathy or other neuropathic
pain, infection, tumor, osteoporosis, trauma, structural deformity
or inflammatory disorders) and planned participation in a specific
4 week multimodal outpatient program (see Therapy). Exclusion
criteria were concomitant autoimmune, chronic, inflammatory,
neoplastic-, and psychiatric diseases, drug abuse and pregnancy as
well as any preexisting long-term medication with opioids, non-
opioid analgesics or co-analgesics. Healthy pain free volunteers
without any signs or history of CLBP and concomitant diseases
were asked for their participation in the study as controls. In total,
37 patients and 25 healthy controls matching the criteria listed
above provided written informed consent and were enrolled in the
study. None of the enrolled individuals had been treated with
corticosteroids or had received immunomodulatory agents cur-
rently or in the past. Acute inflammatory diseases at the time of
blood sampling were ruled out by measurement of body
temperature and laboratory assessment of C-reactive-Protein
(CRP) as wells as total- and differential leucocyte count. This
study is registered on German Clinical Trial Register (Registration
Trial DRKS00005954), but was not registered before enrollment
of participants since all patients received only standard treatment
and no further study-related interventions. The authors confirm
that all ongoing and related trials for this drug/intervention are
registered.
Therapy
The multimodal outpatient program (MRIP, ‘‘Muenchner
Ruecken Intensiv Programm’’) performed at the University of
Munich is a clinically established outpatient program for patients
with chronic low back pain. In line with specific recommendations
for the treatment of chronic disabling low back pain [2,3,28], the
program follows a bio-psycho-social approach and comprises
medical (examination, education), physical (exercise), work-related
and behavioral therapy components. The program is conducted
by specialists from at least four professional groups with different
backgrounds (e.g. physicians, physiotherapists, psychotherapists,
occupational therapists). The group size is limited to 10 patients.
The duration of the program is 4 weeks, 5 days a week and 8 hours
a day.
Outcome assessment
Pain and stress levels were routinely evaluated by standardized
questionnaires before treatment, at the end of the program and six
months after completion of the program (follow-up). Patients were
asked to rate their recalled average pain intensity using an 11-
point numerical rating scale (NRS): 0 means ‘‘no pain’’ and 10
means ‘‘worst pain imaginable’’. Self-perceived stress was evalu-
ated using the Short Questionnaire on Current Burden (KAB,
‘‘Kurzfragebogen zur aktuellen Beanspruchung’’). The KAB is
able to repeatedly determine an individual’s psychological state
under the conditions of acute or chronic stress and is highly
sensitive to short-term or situational changes during a stressful
experience [29]. The rating is based on a 6-point scale ranging
from 1 to 6 for all six matched adjectives. Higher KAB values
indicate increased perceived stress levels. Responders were defined
as patients with improvements in NRS by $50% due to the
treatment program. Healthy controls were asked to fill out
questionnaires once.
Blood sampling
Blood samples were taken from all patients before treatment, at
the end of the program and at the follow-up six months after
completion of the program. Blood samples from healthy volunteers
were taken once at enrollment.
Cytokine Assessment. Blood samples were collected, cen-
trifuged and stored in polypropylene aliquot tubes at 280uC.
Samples were then assessed for levels of T cell related cytokines
using a human cytokine multiplex immunoassay by Myriad Rules-
Based Medicine Inc., Austin, Texas, USA. The multiplex
microbead assay is based on Luminex technology and measures
proteins in a similar manner to standard sandwich ELISA, with
comparable sensitivity and range. Regarding the detection limits,
the LLOQ (Lower Limit of Quantitation) for the cytokines were:
TNF-a: 23.0 pg/ml, IFN-c: 1.5 pg/ml, IL-4: 29.0 pg/ml, IL-6:
11.0 pg/ml, IL-10: 6.9 pg/ml, IL-17: 4.0 pg/ml, IL-23: 0.59 pg/
ml. The LLOQ is the lowest concentration of an analyte in a
sample that can be reliably detected and at which the total error
meets the laboratory’s requirements for accuracy [30].
Flow cytometric staining and analysis
After collection of heparinized venous blood samples, peripheral
blood mononuclear cells (PBMCs) were separated by density
gradient preparation over Ficoll-Uropoline (Sigma Aldrich,
Taufkirchen, Germany). Hereupon, PBMCs were cryopreserved
in RPMI freezing media containing 10% FCS and 10% DMSO
[31] and stored at 230uC for 24 h and then at 2196uC until
measurement. After storage, samples were thawed rapidly in a
water bath at 37uC and washed twice to eliminate DMSO. For
TH1, TH2 and TH17 analysis, cells were stimulated 5 h with cell
stimulation cocktail including protein transport inhibitors (Phorbol
12-myristate 13-acetate (PMA), ionomycin, brefeldin A and
monensin, eBioscience, San Diego, CA, USA) according to the
manufacturer’s protocol. Subsequently, cells were extracellulary
stained with anti-human CD4 antibody and consecutively fixed
and permeabilized (Fix-Perm-Solutions A and B, Life Technolo-
gies, Darmstadt, Germany) for intracellular staining with anti-
human INF-c (detection of TH1 cells), IL-4 (detection of TH2
cells) and IL-17 antibody (detection of TH17 cells, all Biolegend,
San Diego, CA, USA). T cell distribution was measured by FACS
analysis with the Attune Acoustic Focusing Cytometer (Life
Technologies, Carlsbad, USA). Tregs were identified and quan-
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tified using multicolor flow cytometry after surface staining of
PBMCs with mAbs specific for anti-human CD4, CD25 and
CD127 and intracellular staining with an anti-human FoxP3
antibody. The frequencies of CD4+CD25high and
CD4+CD25highCD127lowFoxP3+ T cells were expressed as
percentage of total CD4+ T cells by sequential gating on
lymphocytes. Isotype controls (Biolegend, San Diego, CA, USA)
were given for compensation and confirmation of antibody
specificity.
RNA isolation and synthesis of cDNA
CD4+ cells were isolated from PBMCs by magnetic separation
with Whole Blood CD4 MicroBeads (MACS Miltenyi Biotec,
Auburn, CA, USA). Subsequently, total RNA was isolated using
the mirVana miRNA Isolation Kit followed by a DNase-digest
with Turbo DNA-free Kit (Ambion). Quantity and purity of the
isolated RNA were measured using a NanoDrop ND-1000
spectrophotometer (Peqlab). After amplification of total RNA
using TargetAmp 1-Round aRNA Amplification Kit (Epicentre
Biotechnologies, Madison, WI, USA) and purification using
RNeasy Mini Kit (Qiagen), cDNA synthesis was performed with
SuperScript III First Strand Synthesis System (Invitrogen) and
random hexamers (Qiagen).
Quantitative real-time PCR (qPCR)
Quantitative RT-PCR was performed in duplicates with the
LightCycler 480 instrument (Roche Diagnostics, Mannheim,
Germany) using LightCycler 480 Probes Master and RealTime
ready single assays (Roche Diagnostics) and UPL probes. The
RealTime ready single assays contain target specific primers and a
Universal ProbeLibrary LNA probe. Primer sequences and qPCR
characteristics are given in Table 1. The cycling conditions
comprised an initial denaturation phase at 95uC for 10 min,
followed by 45 cycles at 95uC for 10 s, 60uC for 30 s and 72uC for
1 s. Relative mRNA expression was calculated by Relative
Quantification Software (Roche Diagnostics) using an efficiency-
corrected algorithm with standard curves and reference gene
normalization against the reference genes succinate dehydroge-
nase complex subunit A (SDHA) and TATA box binding protein
(TBP) as described in [32].
Statistical analyses
All statistical analyses were performed using SigmaStat 12.0
(Systat Software, Chicago, USA). Every statistical analysis was
started with testing for normal distribution using the Shapiro Wilk
Test. Testing for differences between groups was accomplished by
the T-Test for all data with normal distribution (IL-17, IL-23,
TGF-b-mRNA, CD25+CD25high) and the nonparametric Mann-
Whitney Rank Sum Test for all data without normal distribution
(IL-6, IL-10, IL-23-mRNA, IFN-c-mRNA, FoxP3-mRNA,
RORcT-mRNA, Tregs, TH17 cells, TH17/Treg Ratio, TH1/
TH2 Ratio). Values are expressed as mean 6 standard deviation
(SD) in the text and figures and p-values#0.05 were considered
statistically significant.
Results
Subjects and treatment variables
23 female and 14 male patients were enrolled. The median age
of the patients at inclusion was 44.5 (range 21–73) years. The
control group consisted of 25 (13 female/12 male) healthy pain
free individuals aged 43.0 (range 24–54) years.
At inclusion, the average pain intensity of the patients was NRS
3.37 (62.4) at rest and NRS 4.18 (62.5) during movement. The
average pain duration was 70.1 (678.3) months. Using the KAB to
evaluate the intensity of self-perceived stress, patients rated
average KAB values at inclusion with 3.31 (60.83). The average
KAB of healthy controls was 1.80 (60.64).
Upon therapy, 13 of 37 patients (35%) showed a significant
reduction of pain scores (NRS) within 4 weeks, as defined by a
decrease of pain ratings of $50%. They were therefore defined as
therapy responders. Follow-up responders were defined as patients
with persisting favorable effects according to the aforementioned
criteria after 6 months.
Serum cytokine profiles
Serum protein levels of TNF-a, IFN-c and IL-4 were neither
detectable in the peripheral blood of CLBP patients nor in blood
samples of healthy controls. Generally, for both CLBP patients
and healthy controls, the serum levels of IL-6, IL-10, Il-17 and IL-
23 were found to be just marginally above the detection
thresholds. No differences were found for IL-6, IL-10 and IL-17
(Figs. 1A, 1B, 1C). However, only levels of the pro-inflammatory
cytokine IL-23 were found to be significantly higher in patients
with CLBP before initiation of therapy as compared to healthy
controls. (IL-23: 0.9460.29 pg/ml in healthy controls vs.
1.2160.43 pg/ml in CLBP patients; p = 0.009; Fig. 1D).
mRNA expression of T cell cytokines
As measurements of specific cytokine profiles in serum turned
out to be not conclusive, we determined the mRNA expression of
cytokines and T cell specific transcription factors directly in the
compartment of CD4+ cells of CLBP patients and healthy
volunteers. By means of qPCR, we evaluated the mRNA
expression of the TH1 cytokines TNF-a and IFN-c, the TH2
cytokines IL-4 and IL-10, FoxP3 and TGF-b indicative for Tregs,
and IL-6, IL-17, IL 23 and the transcription factor RORcT
specific for TH17 cells.
The expression of the TH1 specific cytokine IFN-c did not
exhibit significant differences in CLBP patients as compared to
healthy controls (IFN-c: 4.1963.54 in CLBP patients vs.
3.6062.20 in healthy controls, n.s., Fig. 2A). Expression levels of
TNF-a, IL-4 and IL-10 were neither detectable in CD4+ T cells of
CLBP patients nor in healthy controls. As shown in Fig. 2B, the
expression of IL-23 in CD4+ T cell samples of CLBP patients was
found to be significantly decreased compared to healthy controls
(IL-23: 4.8862.44 in CLBP patients vs. 7.7363.77 in healthy
controls, p = 0.006). The expression of both TGF-b and the
transcription factor FoxP3 was significantly increased in CD4+
cells of CLBP patients compared to healthy controls, thereby
implying an increased Treg abundance (TGF-b: 0.2160.07 in
CLBP patients vs. 0.1460.05 in healthy controls, p = 0.014,
Fig. 3A, FoxP3: 0.2160.14 in CLBP patients vs. 0.1460.06 in
healthy controls, p = 0.009, Fig. 3B). Regarding factors specific for
TH17 cells, the expression of IL-6 and IL-17 was neither
detectable in CD4+ samples of CLBP patients nor in healthy
controls. Expression levels of RORcT did not differ in CLBP
patients and healthy controls (RORcT: 0.02860.02 in CLBP
patients vs. 0.02560.01 in healthy controls, n.s., Fig. 3C). Taken
together, qPCR results promoted the hypothesis that CLBP
patients may exhibit altered distribution patterns of Treg and
TH17 subsets whereas TH1/TH2 balance appeared to be
unchanged.
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CLBP patients exhibit an increased Treg frequency while
the TH17 frequency is decreased
To test this hypothesis, we next evaluated the distribution of T
cell subsets in blood samples of patients and healthy volunteers by
flow cytometric analyses. The relative number of Tregs was
assessed by using two different staining protocols: First, with
antibodies specific for CD4+CD25high cells and second, specific for
CD4+CD25highCD127lowFoxP3+ cells (Gating strategy is displayed
on Fig. 4). TH17 cells were identified by intracellular staining with
anti-human IL-17 antibody (gating strategy is displayed on Fig. 5).
Table 1. RT-PCR Assay Characteristics and Primer Sequences.
Gene Primer Sequence
SDHA Roche RealTime Ready Single Assay ID 102136
TBP Roche RealTime Ready Single Assay ID 101145
FoxP3 Roche RealTime Ready Single Assay ID 113503
IL-4 for 59TGCCTCACATTGTCACTGC 39
rev 59GCACATGCTAGCAGGAAGAAC 39, UPL probe #38
IL-6 for 59GATGAGTACAAAAGTCCTGATCCA 39
rev 59CTGCAGCCACTGGTTCTGT 39, UPL probe #40
IL-10 for 59TGCCTTCAGCAGAGTGAAGA 39
rev 59GCAACCCAGGTAACCCTTAAA 39, UPL probe #67
IL-17 for 59TGGGAAGACCTCATTGGTGT 39
rev 59GGATTTCGTGGGATTGTGAT 39, UPL probe #8
IL-23 for 59CAGCTTCATGCCTCCCTACT 39
rev 59GACTGAGGCTTGGAATCTGC 39, UPL probe #14
TGF-b for 59ACTACTACGCCAAGGAGGTCAC 39
rev 59TGCTTGAACTTGTCATAGATTTCG 39, UPL probe #31
TNF-a for 59CAGCCTCTTCTCCTTCCTGAT 39
rev 59GCCAGAGGGCTGATTAGAGA 39, UPL probe #29
IFN-c for 59GGCATTTTGAAGAATTGGAAAG 39
rev 59TTTGGATGCTCTGGTCATCTT 39, UPL probe #21
RoRcT for 59CAGCGCTCCAACATCTTCT 39
rev 59CCACATCTCCCACATGGAC 39, UPL probe #69
doi:10.1371/journal.pone.0104883.t001
Figure 1. Concentrations of serum cytokines, determined by using a Human Cytokine multiplex immunoassay. No differences are
found analyzing serum protein levels of IL-6, IL-10 and IL-17 between patients and healthy controls (Fig. 1A, 1B, 1C). Protein levels of pro-
inflammatory cytokine IL-23 are significantly higher in the peripheral blood of patients with CLBP compared to healthy controls. Values are expressed
as mean 6 standard deviation. (IL-23: 0.9460.29 pg/ml in healthy controls vs. 1.2160.43 pg/ml in CLBP patients; p = 0.009; Fig. 1D).
doi:10.1371/journal.pone.0104883.g001
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Figure 2. Expression levels of T cell related cytokine mRNA measured by qPCR. TNF-a, IL-4 and IL-10 were neither detectable in CD4+ T
cells of CLBP patients nor in healthy controls. The expression of IFN-c did not exhibit significant differences in CLBP patients as compared to healthy
controls (IFN-c: 4.1963.54 in CLBP patients vs. 3.6062.20 in healthy controls, n.s.; Fig. 2A) whereas IL-23 expression of in CD4+ T cell samples of CLBP
patients was found to be significantly decreased (4.8862.44 in CLBP patients vs. 7.7363.77 in healthy controls, p = 0.006; Fig. 2B).
doi:10.1371/journal.pone.0104883.g002
Figure 3. Expression levels of T cell subset related mRNA measured by qPCR. TGF-b and FoxP3 mRNA expression, specific for Tregs, was
significantly higher in patients with CLBP than in healthy controls (TGF-b: 0.2160.07 in CLBP patients vs. 0.1460.05 in healthy controls, p = 0.014; Fig.
3A), (FoxP3: 0.2160.14 in CLBP patients vs. 0.1460.06 in healthy controls, p = 0.009; Fig. 3B). TH17 specific expression of IL-17 was neither detectable
in CD4+ samples of CLBP patients nor in healthy controls. Expression levels of RORcT did not differ in CLBP patients and healthy controls (RORcT:
0.02860.02 in CLBP patients vs. 0.02560.01 in healthy controls, p = n.s.; Fig. 3C).
doi:10.1371/journal.pone.0104883.g003
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Figure 4. Gating strategy for the detection of Tregs. PBMCs extracellular stained with PerCP labeled anti-human CD4-antibody, PE labeled anti
CD25-antibody, Brilliant Violet (BV570) labeled anti CD127-antibody and intracellular stained with Alexa Fluor (AF488) labeled anti-human FoxP3-
antibody. Lymphocyte population was gated from PBMCs according to forward scatter (FSC) characteristics and side scatter (SSC) characteristics (left).
Gated lymphocytes were then separated in CD4+CD25high cells/T cells (middle) and CD4+CD25highCD127lowFOXP3+ cells/CD4+T cells (right, named
Treg). Upper row represents the result of a healthy control with less CD4+CD25high T cells (3.28%) and less CD4+CD25highCD127lowFoxP3+ T cells
(1.94%) compared to a patient with CLBP (lower row, 5.74% and 3.11%).
doi:10.1371/journal.pone.0104883.g004
Figure 5. Gating strategy for the detection of TH1 and TH17 cells. PBMCs stimulated with cell stimulation cocktail for 5 h followed by
intracellular staining with Brilliant Violet (BV421) labeled anti-human IL-17 antibody and FITC labeled anti-human IFN-c antibody.
doi:10.1371/journal.pone.0104883.g005
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With both Treg staining protocols, a significantly increased
frequency of Tregs was seen in CLBP patients as compared to
healthy controls. FACS analysis applying the CD4+CD25high
staining protocol resulted in 4.4560.88% CD4+CD25high cells in
CLBP patients vs. 3.4960.5%, CD4+CD25high cells in healthy
controls (p,0.001, Figure 6A). CD4+CD25highCD127lowFoxP3+
staining as a more specific staining protocol for Tregs revealed
similar results with 2.8961.07% Tregs in CLBP patients vs.
1.9360.66% Tregs in healthy controls (p = 0.001, Figure 6B). The
frequency of TH17 cells, however, was found to be significantly
decreased in CLBP patients as compared to healthy volunteers
(TH17: 0.4660.24% in CLBP patients vs. 1.1460.73% in healthy
controls, p = ,0.001, Figure 6C). Conclusively, ratios of Th17/
CD4+CD25high resp. Th17/CD4+CD25highCD127lowFoxP3+
were significantly decreased in CLBP patients as compared to
healthy controls (Th17/CD4+CD25high: 0.1260.08 in CLBP
patients vs. 0.3360.23 in healthy controls, p,0.001, Fig. 7A;
Th17/CD4+CD25highCD127lowFoxP3+: 0.2360.17 in CLBP pa-
tients vs. 0.6460.79 in healthy controls, p,0.001, Fig. 7B).
TH1/TH2 balance is not altered in CLBP patients
As depicted in Fig. 7C, TH1/TH2 balance did not reveal
significant differences between CLBP patients and healthy
controls; however, a trend towards a decreased TH1/TH2 ratio
was observed (TH1/TH2: 9.7667.27 in CLBP patients vs.
14.72612.81 in healthy controls, p = n.s.).
T cell ratios remain altered in CLBP patients after
multimodal therapy
To evaluate the impact of therapeutic interventions on the
observed T cell subset alterations in CLBP patients, the
distribution of TH cells subsets (TH1, TH2, TH17 and Tregs)
was analyzed in the group of therapy responders before,
immediately after therapy and 6 months later. As depicted in
Fig. 8A, these patients showed an ongoing decrease of NRS by $
50% due to the treatment program. The pain reduction was also
accompanied by a decrease of the KAB values. However, as
shown in Figure 8B, this therapeutic effect was not reflected in any
respective adaptation of the T cell subsets.
Discussion
Pathomechanisms driving the chronification of low back pain
still remain largely elusive. While a growing body of evidence
suggests a pivotal role of adaptive immune responses in the
pathogenesis of chronic pain, these issues have not conclusively
been analyzed for CLBP, yet.
Our results indicate that CLBP is associated with characteristic
alterations of T helper cell subsets: The ratio between regulatory T
cells, playing a vital role in controlling adaptive immune responses,
and TH17 cells, one of the key effector T cells mediating
autoimmunity [33], was significantly decreased. We further
provide evidence that these alterations persist even in these
patients exhibiting significant pain reduction after participation in
a standardized multimodal therapy program [3].
Assuming that cytokines as central mediators of cellular
immunity may mirror immune cell functions, we first analyzed
seven T cell related cytokines (TNF-a, IFN-c, IL-4, IL-6, IL-10,
IL-17, IL-23) in serum samples of CLBP patients and healthy
controls. TNF-a, IFN-c and IL-4 were below the detection limits
in patients as well as in healthy controls, and the results of the
remaining four analytes were only slightly above the detectable
limit. Values for the proinflammatory cytokines IL-6 and IL-17 in
Figure 6. Flow cytometric quantification of Tregs and TH17 cells. Results show significantly higher percentage of anti-inflammatory Tregs in
patients with CLBP in both staining protocols (CD4+CD25high cells: 4.4560.88% in CLBP patients vs. 3.4960.53% in healthy controls, p,0.001; Fig. 6A),
(CD4+CD25highCD127lowFoxP3+ cells: 2.8961.07% in CLBP patients vs. 1.9360.66% in healthy controls, p = 0.001; Fig. 6B). Number of TH17 cells as
percentage of T cells in peripheral blood show significantly lower percentage of pro-inflammatory TH17 cells in patients with CLBP (TH17 cells:
0.4660.24% in CLBP patients vs. 1.1460.73% in healthy controls, p,0.001; Fig. 6C).
doi:10.1371/journal.pone.0104883.g006
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blood samples of CLPB patients were slightly elevated as
compared to controls. However, this finding may be of limited
clinical relevance as normal plasma concentrations for IL-6 of
healthy controls are about 1 pg/ml with immense increases
in situations of severe systemic infection ranging up to 10.000-fold.
Our results demonstrate only an 1.5-fold increase in IL-6 levels in
patients with CLBP, which could even occur after physical activity
or in obesity [34]. However, the relevance of cytokine measure-
ments should generally be regarded with caution as serum levels of
most cytokines are influenced by a complex interplay of
macrophages/monocytes, fibroblasts, endothelial2/epithelial cells
and dendritic cells thus complicating the extrapolation from
plasma cytokines to immune cell functions. Moreover, ranges of
detection exhibits considerable variances between the different
assays used [35]. Even different types of Luminex-based platforms
exhibit differences in their ability to measure serum levels of
cytokines and thus, may be more useful in studies in which relative
rather than absolute changes in cytokines are of interest [36,37].
Overall, these data suggest that serum levels of cytokines are not
suitable to monitor the adaptive immune response in CLBP and
prompted us to analyze the expression of cytokines directly in the
compartment of CD4+ cells as central players of the T cell
response. While no differences in the expression of TH1 and TH2
cytokines were observed, qPCR results clearly pointed to an
increased abundance of Tregs in CLBP patients, as expression of
both TGF-b and the transcription factor FoxP3 were significantly
increased. Moreover, expression of IL-23 was clearly decreased
supporting the assumption that TH17 frequency may be reduced.
IL-17 and RORcT, however, did not differ significantly between
CLBP and controls which may be due to the fact that the subset of
TH17 cells per se is only less than 2% of CD4+ cells. Thus,
resolving differences of cytokine expression without prior cell
sorting may be difficult. The opposite results of increased IL-23
protein levels and decreased IL23-mRNA-expression is in line
with a wide body of literature showing a big discrepancy between
mRNA expression and protein levels as a result of control
mechanisms. These can affect post-transcriptional, translational
and protein degrading processes [38,39].
Our findings encouraged us to investigate T cell subset
compositions by flow cytometric analyzes. We used standard
staining procedures to identify TH1, TH2, and TH17 cells,
whereas for identification of anti-inflammatory Tregs, both classic
extracellular staining of CD4+CD25high and a more specific extra-
and intracellular staining of CD4+CD25highCD127lowFoxP3+ was
applied. As activated human T cells can transiently express FoxP3
and CD25, differentiation of Tregs from activated effector T cells
by only using these two markers may suffer from inaccuracies.
CD127 is a newly described surface marker that allows
distinguishing regulatory T cells from other CD25+ cells [40].
For TH17 identification, we chose two experimental approaches:
determination the mRNA expression of the TH17 specific
transcription factor RORcT by qPCR, and FACS analyses of
IL-17 production, which has revealed as a very reliable method to
identify TH17 cells [41]. However, flow cytometry staining
protocols combining IL-17 with further markers, e.g. CD161 or
CCR6, may further refine these measurements and thus may be
implemented in future studies.
Flow cytometry clearly proved the assumed alterations of the
TH17/Treg balance, as a significantly increased frequency of
Tregs and decreased frequency of TH17 cells was observed in our
CLBP patients. Even in flow cytometric analyzes, no differences in
the TH1/TH2 ratio were detectable. There are several investi-
Figure 7. Ratios of TH17/CD4+CD25high, TH17/Tregs and TH1/TH2 cells. Ratios of Th17/CD4+CD25high and Th17/CD4+CD25highCD127low-
FoxP3+ were significantly decreased in CLBP patients as compared to healthy controls (Th17/CD4+CD25high: 0.1260.08 in CLBP patients vs.
0.3360.23% in healthy controls, p,0.001; Fig. 7A), (Th17/CD4+CD25highCD127lowFoxP3+: 0.2360.17 in CLBP patients vs. 0.6460.79 in healthy
controls, p,0.001; Fig. 7B). Ratio of TH1/TH2 cells in peripheral blood of patients with CLBP and healthy controls were tendencially decreased in
patients with CLBP, but did not reach significance (9.7667.27 in CLBP patients vs. 14.72612.81 in healthy controls, p = 0.19, Fig. 7C).
doi:10.1371/journal.pone.0104883.g007
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gations which point to a beneficial role of anti-inflammatory cells
and cytokines together with a detrimental function of a pro-
inflammatory immune response in pain patients [6,7,8,9]. In
contrast to these findings, our results showing an anti-inflamma-
tory shift on cellular level are in accordance with other chronic
diseases like mild depression or chronic fatigue syndrome [42,43].
A potential explanation for our findings on TH17/Treg balance
may therefore be that pain-related, long lasting chronic stress and
fatigue induces an ongoing dysregulation of immune cells towards
an anti-inflammatory phenotype [44,45,46]. On the other hand, it
may also be discussed that dysregulation of the TH17/Treg
balance may exist first, thus predisposing the affected individuals
to experience chronification of pain symptoms. The latter theory
may be supported by our surprising findings that the observed
TH17/Treg imbalance persisted despite clinical improvement
after multimodal therapy even after a follow-up period of 6
months.
In summary, we found a persisting TH17/Treg imbalance with
an increased count of anti-inflammatory Tregs and a decreased
number of pro-inflammatory TH17 cells in peripheral blood of
CLBP patients pointing to a strong association between chronic
pain and immune suppression rather than immune activation.
Importantly, these findings are not reflected by serum cytokine
concentration, indicating a major role of specific T cell subset
measurements in the analysis of pain-related immune responses.
Taken together, the results of the current study suggest an
involvement of TH17/Treg in the pathogenesis of CLBP and
emphasize the importance of these cells in the crosstalk of pain and
immune response.
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